Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis
Authors:
- Jane C FigueiredoJFJane C Figueiredo
- Julia A KnightJKJulia A Knight
- Stewart ChoSCStewart Cho
- Sevtap SavasSSSevtap Savas
- U Venus OnayUOU Venus Onay
- Laurent BriollaisLBLaurent Briollais
- Pamela J GoodwinPGPamela J Goodwin
- John R McLaughlinJMJohn R McLaughlin
- Irene L AndrulisIAIrene L Andrulis
- Hilmi OzcelikHOHilmi Ozcelik
Open Access
- 14 June 2007
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 7 (1) , 1-8
Abstract
Background: cMyc and p27 are key genes implicated in carcinogenesis. Whether polymorphisms in these genes affect breast cancer risk or prognosis is still unclear. In this study, we focus on a rare non-synonymous polymorphism in cMyc (N11S) and a common polymorphism in p27 (V109G) and determine their role in risk and prognosis using data collected from the Ontario Breast Cancer Family Registry.Methods: Risk factor data was collected at baseline on a large group of women (cases = 1,115 and population-based controls = 710) and clinical data (including treatment and follow-up) were collected prospectively by periodic review of medical records for a subset of cases (N = 967) for nearly a decade. A centralized pathology review was conducted. Unconditional logistic regression was used to determine the association of polymorphisms with breast cancer risk and the Cox proportional hazards model was used to determine their association with survival.Results: Our results suggest that while cMyc-N11S can be considered a putatively functional polymorphism located in the N-terminal domain, it is not associated with risk, tumor characteristics or survival. The p27-G109 allele was associated with a modest protective effect in adjusted analyses and higher T stage. We found no evidence to suggest that p27-V109G alone or in combination with cMyc-N11S was associated with survival. Age at onset and first-degree family history of breast or ovarian cancer did not significantly modify the association of these polymorphisms with breast cancer risk.Conclusion: Further work is recommended to understand the potential functional role of these specific non-synonymous amino acid changes and a larger, more comprehensive investigation of genetic variation in these genes (e.g., using a tagSNP approach) in combination with other relevant genes is needed as well as consideration for treatment effects when assessing their potential role in prognosis.Keywords
This publication has 29 references indexed in Scilit:
- Influence of young age at diagnosis and family history of breast or ovarian cancer on breast cancer outcomes in a population-based cohort studyBreast Cancer Research and Treatment, 2006
- Variant genotypes of CDKN1A and CDKN1B are associated with an increased risk of breast cancer in Chinese womenInternational Journal of Cancer, 2006
- c-MYC Asn11Ser is associated with increased risk for familial breast cancerInternational Journal of Cancer, 2005
- Candidate nsSNPs that can affect the functions and interactions of cell cycle proteinsProteins: Structure, Function, and Bioinformatics, 2004
- Association between the V109G Polymorphism of thep27Gene and the Risk and Progression of Oral Squamous Cell CarcinomaClinical Cancer Research, 2004
- The V109G Polymorphism of the p27 Gene CDKN1B Indicates a Worse Outcome in Node-Negative Breast Cancer PatientsTumor Biology, 2004
- Characteristics Associated with Participation at Various Stages at the Ontario Site of the Cooperative Family Registry for Breast Cancer StudiesAnnals of Epidemiology, 2002
- The Cooperative Familial Registry for Breast Cancer Studies: design and first year recruitment rates in OntarioJournal of Clinical Epidemiology, 2001
- c-Myc in breast cancer.Endocrine-Related Cancer, 2000
- MYC oncogenes and human neoplastic diseaseOncogene, 1999